France Healthcare Market Report 2026: HAS Market Access, Assurance Maladie, and Commercial Intelligence

The French healthcare market is estimated at EUR 255–270 billion in 2026, representing approximately 12.1% of GDP. France operates a universal healthcare system (Assurance Maladie, colloquially called "la Sécu") funded through payroll contributions and general taxation. Approximately 77% of healthcare costs are covered by the Assurance Maladie (CNAM), with complementary insurance (mutuelles and assurances complémentaires) covering an additional 13% on average, leaving approximately 10% as out-of-pocket expenditure. France has approximately 3,000 hospitals (public and private), 74,000 community pharmacies, and 220,000+ physicians.

The French pharmaceutical market is estimated at EUR 32–35 billion in 2026, making it the second-largest pharmaceutical market in the EU after Germany. The Assurance Maladie reimburses approved medicines at rates ranging from 15% to 100% depending on therapeutic value. HAS (Haute Autorité de Santé) Transparency Commission assesses all new medicines for SMR (Service Médical Rendu, medical benefit) and ASMR (Amélioration du Service Médical Rendu, improvement of medical benefit), with ASMR ratings I–V (I = major improvement, V = no improvement demonstrated). Price negotiations for reimbursed products are conducted by CEPS (Comité Économique des Produits de Santé).

The French HAS (Haute Autorité de Santé) Transparency Commission conducts benefit assessment for all new medicines seeking reimbursement. The two-stage assessment assigns: (1) SMR (medical benefit level) — the absolute benefit rating (major/important/moderate/low/insufficient) that determines reimbursement rate; and (2) ASMR (improvement of medical benefit) — the comparative added benefit against the comparator (ratings I–V). Products with ASMR I–III typically receive a price premium versus existing treatments. Products with ASMR IV or V are generally priced at or below the comparator. Early access (Autorisation d'Accès Précoce, AAP — replacing the former ATU system) enables HAS-assessed pre-approval access for promising therapies. Price negotiations with CEPS follow HAS assessment.

The five largest therapy areas in the French pharmaceutical market by Assurance Maladie reimbursement spend are: oncology (fastest-growing, driven by immunotherapy, targeted therapy, and cancer hospital budgets); cardiovascular (high volume: statins, anticoagulants, antihypertensives); immunology and biologics (TNF inhibitors, IL-17/23 inhibitors, JAK inhibitors, with growing biosimilar penetration); diabetes (GLP-1 agonists growing rapidly, insulin at high volume); and respiratory (COPD biologics, dupilumab for severe asthma, ICS/LABA combinations). The AAP early access pathway is particularly active in oncology and rare diseases.

The French medical devices market is estimated at EUR 14–16 billion in 2026. ANSM (Agence nationale de sécurité du médicament et des produits de santé) is the national competent authority for market surveillance under EU MDR. Medical devices seeking reimbursement through the Assurance Maladie must be listed on the LPP (Liste des Produits et Prestations). HAS CNEDIMTS (Commission nationale d'évaluation des dispositifs médicaux et des technologies de santé) assesses the ASA (added value) of new devices for LPP listing. The Forfait Innovation pathway enables early conditional reimbursement for genuinely innovative devices.

CEPS (Comité Économique des Produits de Santé), the French government's pricing committee, negotiates ex-factory prices for all medicines seeking Assurance Maladie reimbursement following HAS Transparency Commission assessment. Statutory negotiation windows run 180 days, though in practice discussions frequently extend to 9–18 months for complex or high-cost products. ASMR ratings from HAS directly shape CEPS's negotiating position: ASMR I–III ratings support premium pricing versus the nearest comparator, while ASMR IV or V ratings typically anchor the price at or below the comparator level. CEPS also references list prices across a basket of roughly eleven other European countries when setting French prices, and increasingly relies on confidential managed-entry agreements, including outcomes-based and volume-capped arrangements, for expensive oncology, rare disease, and gene therapy products. Once CEPS and the manufacturer reach agreement, the price and reimbursement rate are published in the Journal Officiel, which formally triggers Assurance Maladie coverage.

ONDAM (Objectif National de Dépenses d'Assurance Maladie) is France's annual national target for Assurance Maladie spending, voted each year by Parliament as part of the Social Security financing law (LFSS). ONDAM sets an overall ceiling across hospital care, ambulatory medicine, medico-social services, and pharmaceutical spending, and its year-on-year growth rate — typically in the low single digits — is a closely watched signal of the government's fiscal appetite for healthcare and pharmaceutical spending. When actual spending threatens to breach the ONDAM target, the government and CEPS can respond with price cuts, rebate clawbacks (clause de sauvegarde), and volume-based conventions with manufacturers to bring spending back in line. For pharmaceutical companies, ONDAM pressure has historically translated into more aggressive CEPS price negotiations, faster generic and biosimilar substitution targets, and periodic across-the-board price revision campaigns on mature products.

France permits pharmacist-level substitution of biosimilars for reference biologics at the point of treatment initiation, and since 2022 has extended substitution rights to certain products even during ongoing treatment, subject to physician non-objection and patient information. The Assurance Maladie and CEPS actively promote biosimilar uptake through pharmacist substitution incentives, hospital-level prescribing targets embedded in GHT (Groupement Hospitalier de Territoire) formulary policies, and price convergence rules that require biosimilars to launch at a discount to the originator. Biosimilar penetration is most advanced in filgrastim, insulin glargine, and adalimumab, with growing uptake in oncology biosimilars such as trastuzumab, bevacizumab, and rituximab. For manufacturers, biosimilar entry typically triggers CEPS-mandated price reductions on the originator product as well, making the timing of a first biosimilar launch a significant commercial planning variable in France.

BioNixus delivers pharmaceutical and healthcare market research in france: regulator-aware access intelligence, hospital consumption analogues, physician and payer qualitative programmes, and launch evidence under EphMRA and BHBIA governance with GDPR-aligned fieldwork for multinational sponsors. Teams receive decision-ready outputs validated against national policy and institution-level adoption—not desk extrapolation from unrelated regions.

BioNixus supports france-based pharmaceutical companies expanding into GCC and MENA markets with SFDA and MOHAP regulatory intelligence, NUPCO and hospital procurement tracking in Saudi Arabia, UAE insurer and formulary research, physician panels across GCC countries, and comparative france versus GCC market intelligence. GCC expansion is a distinct service line with its own tender and access calendars—see our GCC pharmaceutical market report for regional context. Launch assumptions should be validated market by market rather than from a single Gulf average.